Through most of the 20th century, the piobneering research in the use of psychedelics to treat mental health disorders has largely come out of the US.

Article presenting the life-changing impact of the rare and debilitating headache condition SUNHA, mentioning Beckley Psytech’s upcoming clinical trial exploring the effects of psilocybin as a treatment.

Article on the life-changing effects of the rare headache condition SUNHA, featuring a quote from Beckley Psytech’s Chief Medical Advisor Dr Fiona Dunbar, on our upcoming clinical trial exploring psilocybin as a treatment.

Beckley Psytech passed a huge milestone recently. We received Clinical Trial Authorisation from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to explore the effects of psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA).

Beckley Psytech, a company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer with immediate effect.

Plants In a two-part blog series Beckley Psytech research scientist Anya Ermakova explores the history of indigenous use of 5-MeO-DMT, the psychedelic agent that is the focus of our lead research programme. In part one she looks at plants containing 5-MeO-DMT and the cultures that have used them for medicinal and spiritual purposes throughout history.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to explore the effects of psychedelic agent psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare and debilitating headache condition.

Exclusive news article on the $18.6m funding round, featuring Beckley Psytech’s pitch deck and comments from CEO Cosmo Feilding-Mellen.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to explore the effects of psychedelic agent psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare and debilitating headache condition.